Literature DB >> 22502948

Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

Alice P Chen1, Ann Setser, Milan J Anadkat, Jonathan Cotliar, Elise A Olsen, Benjamin C Garden, Mario E Lacouture.   

Abstract

Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, which requires accurate cataloging and grading of side effects. The Common Terminology Criteria for Adverse Events Version 4.0 is a descriptive terminology and grading system that can be used for uniform reporting of adverse events. A proper understanding of this standardized classification system is essential for dermatologists to properly communicate with all physicians caring for patients with cancer.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22502948     DOI: 10.1016/j.jaad.2012.02.010

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  114 in total

Review 1.  The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015.

Authors:  Roni P Dodiuk-Gad; Cristina Olteanu; Wen-Hung Chung; Neil H Shear
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

2.  Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Authors:  Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2019-04-09       Impact factor: 3.167

3.  Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and OAE-based representation and analysis of adverse events in patients treated with cancer drugs.

Authors:  Mei U Wong; Rebecca Racz; Edison Ong; Yongqun He
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

4.  Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Authors:  Alexander Drilon; Anne A Eaton; Katja Schindler; Mrinal M Gounder; David R Spriggs; Pamela Harris; S Percy Ivy; Alexia Iasonos; Mario E Lacouture; David M Hyman
Journal:  Cancer       Date:  2016-02-24       Impact factor: 6.860

Review 5.  [Laser and light therapy for treatment of radiation dermatitis].

Authors:  H-J Laubach; J Robijns
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

6.  Transcatheter arterial embolization of hypervascular tumors with HepaSphere: prospective multicenter open label clinical trial of microspheres in Japan.

Authors:  Takao Hiraki; Jun Koizumi; Yasuaki Arai; Yasuo Sakurai; Hiromitsu Kumada; Yoshihiro Nambu; Shinichi Hori
Journal:  Jpn J Radiol       Date:  2015-06-26       Impact factor: 2.374

7.  Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.

Authors:  Gregory S Phillips; Azael Freites-Martinez; Jennifer Wu; Donald Chan; Gabriella Fabbrocini; Matthew D Hellmann; Mario E Lacouture
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 8.  A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.

Authors:  Alexandre Chan; Michael C Cameron; Benjamin Garden; Christine B Boers-Doets; Katja Schindler; Joel B Epstein; Jennifer Choi; Laura Beamer; Eric Roeland; Elvio G Russi; René-Jean Bensadoun; Yi Ling Teo; Raymond J Chan; Vivianne Shih; Jane Bryce; Judith Raber-Durlacher; Peter Arne Gerber; César O Freytes; Bernardo Rapoport; Nicole LeBoeuf; Vincent Sibaud; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2015-01-07       Impact factor: 3.603

9.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

10.  Platelet gel in cutaneous radiation dermatitis.

Authors:  Vincenzo Iervolino; Gaetano Di Costanzo; Rosa Azzaro; Anna Maria Diodato; Catia Addolorata Di Macchia; Tommaso Di Meo; Arnolfo Petruzziello; Giovanna Loquercio; Paolo Muto; Gaetano Apice; Carmela Cacciapuoti
Journal:  Support Care Cancer       Date:  2012-11-13       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.